These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25611241)

  • 1. Breast Cancer Molecular Subtypes and Oxidative DNA Damage.
    Jakovcevic D; Dedic-Plavetic N; Vrbanec D; Jakovcevic A; Jakic-Razumovic J
    Appl Immunohistochem Mol Morphol; 2015; 23(10):696-703. PubMed ID: 25611241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.
    Karihtala P; Kauppila S; Soini Y; Arja-Jukkola-Vuorinen
    BMC Cancer; 2011 Jun; 11():262. PubMed ID: 21693047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis.
    Karihtala P; Kauppila S; Puistola U; Jukkola-Vuorinen A
    Histopathology; 2011 May; 58(6):854-62. PubMed ID: 21585424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased formation of oxidative DNA damage, 8-hydroxy-2'-deoxyguanosine, in human breast cancer tissue and its relationship to GSTP1 and COMT genotypes.
    Matsui A; Ikeda T; Enomoto K; Hosoda K; Nakashima H; Omae K; Watanabe M; Hibi T; Kitajima M
    Cancer Lett; 2000 Apr; 151(1):87-95. PubMed ID: 10766427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of oxidative DNA damage evaluated by 8-hydroxy-2'-deoxyguanosine in patients undergoing radical nephrectomy for renal cell carcinoma.
    Miyake H; Hara I; Kamidono S; Eto H
    Urology; 2004 Nov; 64(5):1057-61. PubMed ID: 15533518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis.
    Musarrat J; Arezina-Wilson J; Wani AA
    Eur J Cancer; 1996 Jun; 32A(7):1209-14. PubMed ID: 8758255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of 8-hydroxy-2'-deoxyguanosine in solid tumors: a meta-analysis.
    Qing X; Shi D; Lv X; Wang B; Chen S; Shao Z
    BMC Cancer; 2019 Oct; 19(1):997. PubMed ID: 31651287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease.
    Bolner A; Pilleri M; De Riva V; Nordera GP
    Clin Lab; 2011; 57(11-12):859-66. PubMed ID: 22239015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organochlorines and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in cancerous and noncancerous breast tissue: do the data support the hypothesis that oxidative DNA damage caused by organochlorines affects breast cancer?
    Charles MJ; Schell MJ; Willman E; Gross HB; Lin Y; Sonnenberg S; Graham ML
    Arch Environ Contam Toxicol; 2001 Oct; 41(3):386-95. PubMed ID: 11503078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 8-hydroxy-2' -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis.
    Valavanidis A; Vlachogianni T; Fiotakis C
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2009 Apr; 27(2):120-39. PubMed ID: 19412858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma.
    Murtas D; Piras F; Minerba L; Ugalde J; Floris C; Maxia C; Demurtas P; Perra MT; Sirigu P
    Oncol Rep; 2010 Feb; 23(2):329-35. PubMed ID: 20043092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis.
    Karihtala P; Winqvist R; Syväoja JE; Kinnula VL; Soini Y
    Eur J Cancer; 2006 Oct; 42(15):2653-9. PubMed ID: 16996262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 8-Hydroxy-2'-deoxyguanosine expression predicts outcome of esophageal cancer.
    He H; Zhao Y; Wang N; Zhang L; Wang C
    Ann Diagn Pathol; 2014 Dec; 18(6):326-8. PubMed ID: 25240715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrative and oxidative DNA damage as potential survival biomarkers for nasopharyngeal carcinoma.
    Huang YJ; Zhang BB; Ma N; Murata M; Tang AZ; Huang GW
    Med Oncol; 2011 Mar; 28(1):377-84. PubMed ID: 20339958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
    Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.